ANGIORUS (Angiorus)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceHesperidin + DiosminHesperidin + Diosmin
Similar drugsTo uncover
  • ANGIORUS
    pills inwards 
    SYNTHESIS, OJSC     Russia
  • Venarus®
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Venarus®
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Diovenges
    pills inwards 
    FORP, CJSC     Russia
    • Dosage form: & nbspfilm-coated tablets
    Composition:

    For 1 tablet:

    Active substances: Hesperidin - 50 mg, diosmin - 450 mg;

    Excipients: hypromellose (hydroxymethylpropylcellulose) 6.5 mg, lactose monohydrate 42 mg, talc 22.8 mg, magnesium stearate 7.6 mg, carboxymethyl starch sodium (sodium starch glycolate) 22.8 mg, microcrystalline cellulose 158.3 mg;

    Shell composition: opadraj II yellow - 22,8 mg;

    Composition of the Fallen II yellow: Macrogol-4000 (polyethylene glycol-4000) - 4.6056 mg, titanium dioxide - 1.6188 mg, talc - 3.3744 mg, polyvinyl alcohol - 9.100 mg, iron-oxide oxide yellow - 4,0812 mg.

    Description:

    Biconvex tablets of oval form, covered with a film coating of yellow-brown color. Type of tablet on the break - from light yellow to grayish-yellow color.

    Pharmacotherapeutic group:Venotonizing and venoprotective agent
    ATX: & nbsp

    C.05.C.A.53   Diosmin in combination with other drugs

    Pharmacodynamics:

    It has venotonic and angioprotective properties.The drug reduces the extensibility of veins and venous congestion, reduces the permeability of capillaries and increases their resistance, improves microcirculation and lymph flow. With systematic use reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of an organic and functional nature.

    Pharmacokinetics:

    The main excretion of the drug occurs through the intestine. About 14% of the taken amount of the drug is excreted by the kidneys. The half-life is 11 hours.

    The drug is subject to active metabolism, which is confirmed by the presence of phenolic acids in the urine.

    Indications:

    Therapy of symptoms of venous-lymphatic insufficiency:

    - pain;

    - convulsions of the lower limbs;

    - sensation of heaviness and raspiraniya in the legs;

    - "fatigue" of the feet.

    Therapy of manifestations of venous-lymphatic insufficiency:

    - swelling of the lower extremities;

    - trophic changes in the skin and subcutaneous tissue;

    - Venous trophic ulcers.

    Symptomatic therapy of acute and chronic hemorrhoids.

    Contraindications:

    Hypersensitivity, the period of breastfeeding.

    Patients with rare hereditary diseases, such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.
    Pregnancy and lactation:

    Experiments on animals did not reveal teratogenic effects.

    To date, there have been no reports of undesirable effects in the use of the drug by pregnant women.

    Due to the lack of data on the excretion of the drug in breast milk, it is not recommended to take the drug during the period of breastfeeding.

    Reproductive toxicity studies showed no effect on reproductive function in rats of both sexes.

    Dosing and Administration:

    Inside, during a meal.

    With venous-lymphatic insufficiency - 2 tablets per day (for one or two doses): morning, afternoon and / or evening.

    The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

    In acute hemorrhoids - 6 tablets per day: 3 tablets in the morning and 3 tablets in the evening for 4 days, then 4 tablets per day: 2 tablets in the morning and 2 tablets in the evening for the next 3 days.

    The recommended dose for chronic hemorrhoids is 2 tablets per day.

    Side effects:

    The frequency of unfavorable adverse reactions is given in accordance with the WHO classification: very often (≥1 / 10); often (≥1 / 100, <1/10); infrequently (≥1 / 1000, <1/100); rarely (≥1 / 10,000, <1/1000); very rarely (<1/10 000, including individual messages); the frequency is unknown (the frequency can not be calculated from the available data).

    From the central nervous system:

    Rarely: dizziness, headache, general malaise.

    From the digestive system:

    Often: diarrhea, indigestion, nausea, vomiting.

    Infrequently: colitis.

    The frequency is unknown: pain in the abdomen.

    Allergic reactions:

    Rarely: skin rash, itchy skin, hives.

    The frequency is unknown: isolated edema of the face, lips, eyelids. In exceptional cases angioedema.

    Inform your doctor about any unwanted reactions and sensations, including those not mentioned in this manual, as well as changes in laboratory parameters against the background of therapy.

    Overdose:

    Data on overdose are absent.

    Interaction:

    There is no data on interactions with other drugs.

    You should inform your doctor about all medications you take.

    Special instructions:

    Before starting to take the drug ANGIORUS it is recommended to consult a doctor.

    With an exacerbation of hemorrhoids, the appointment of ANGIORUS does not replace the specific treatment of other anal disorders.

    Duration of treatment should not exceed the time specified in the section "Method of administration and dose".

    In the event that the symptoms do not disappear after the recommended course of therapy, a proctologic examination should be performed and the therapy used should be reviewed.

    In the presence of violations of venous circulation, the maximum effect of treatment is provided by combining therapy with a healthy (balanced) way of life: it is advisable to avoid long exposure to the sun, prolonged stay on legs, and it is also recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings that help improve blood circulation.

    Seek medical attention immediately if your condition worsens or does not improve during treatment.

    Effect on the ability to drive transp. cf. and fur:

    Does not affect.

    Form release / dosage:

    Tablets, film-coated, 50 mg + 450 mg.

    Packaging:

    For 10 tablets in contour mesh packaging made of polyvinylchloride film and aluminum foil printed lacquered.

    For 20, 30, 60 tablets in cans of polymeric.

    Each jar, 2, 3, 6 contour squares with instruction for use is placed in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of no higher than 30 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-004167
    Date of registration:28.02.2017
    Expiration Date:28.02.2022
    The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspSYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products SYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products Russia
    Information update date: & nbsp31.03.2017
    Illustrated instructions
      Instructions
      Up